Primary and acquired immunodeficiencies like HIV/AIDS are associated with a high prevalence of skin and mucosal diseases caused by the Human Papillomaviruses (HPV), as well as an accelerated progression to HPV-related cancers. Dr. Lisco`s primary focus is on delineating the genetic, immunological, and molecular determinants of the persistence, regression, or progression of HPV-related diseases to inform innovative preventive and therapeutic strategies. The translational workflow of the laboratory is based on the integration of clinical protocols focused on the identification of clinical and epidemiological predictors of severe HPV-related diseases with studies on host genetics and tissue-specific immunopathogenesis at the skin and mucosal barriers, eventually informing personalized interventional clinical protocols.
Andrea Lisco, M.D., Ph.D.
Chief, Mucosal and Cutaneous Viral Immunopathogenesis Unit
Lasker Clinical Research Scholar
Education:
M.D., University of Bari, Italy
Ph.D., University of Padua, Italy
Derek MacMath, M.D.
Clinical Fellow
Education:
B.S., 2014, Molecular and Cellular Biology, Italian, Johns Hopkins University, Baltimore, MD
M.D., 2019, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Internal Medicine/Pediatrics Residency, 2023, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX
Amay Shah, B.S.
Postbaccalaureate IRTA Fellow
Education:
B.S., 2023, Human Biology and Society + Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles
Amay Shah is currently working with Dr. Andrea Lisco on clinical and translational research focused on observing T-cell responses to HPV in patients with primary and acquired immunodeficiencies. His current project involves observing the HIV Reservoir in HPV-specific T cells and characterizing T-cell responses to HPV in patients with HPV and HIV co-infection.
Peiying Ye, Ph.D.
Biologist
Languages Spoken: Chinese
Mapping the host determinants of HPV-related diseases in immunocompromised hosts (EPIC). Development of novel preventive and therapeutic strategies for severe HPV-related disease (NEPTUNE).
